RGX-104
99%
- Product Code: 102301
CAS:
610318-03-1
| Molecular Weight: | 632.54 g./mol | Molecular Formula: | C₃₄H₃₄Cl₂F₃NO₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
RGX-104 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a small molecule activator of the liver X receptor (LXR), which plays a critical role in regulating cholesterol homeostasis and immune responses. By activating LXR, RGX-104 has shown promise in enhancing the body's anti-tumor immune response. This is achieved through the upregulation of apolipoprotein E (ApoE), which in turn promotes the recruitment and activation of immune cells, such as dendritic cells and cytotoxic T cells, within the tumor microenvironment.
Preclinical studies suggest that RGX-104 may be effective in treating various cancers, particularly those resistant to conventional therapies, such as non-small cell lung cancer, melanoma, and ovarian cancer. Its ability to modulate the immune system and target tumor-associated macrophages makes it a potential candidate for combination therapies with immune checkpoint inhibitors or other immunotherapeutic agents. Research is ongoing to further evaluate its efficacy, safety, and potential as a novel cancer treatment.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White To Off-White Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿7,524.00 |
+
-
|
RGX-104
RGX-104 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a small molecule activator of the liver X receptor (LXR), which plays a critical role in regulating cholesterol homeostasis and immune responses. By activating LXR, RGX-104 has shown promise in enhancing the body's anti-tumor immune response. This is achieved through the upregulation of apolipoprotein E (ApoE), which in turn promotes the recruitment and activation of immune cells, such as dendritic cells and cytotoxic T cells, within the tumor microenvironment.
Preclinical studies suggest that RGX-104 may be effective in treating various cancers, particularly those resistant to conventional therapies, such as non-small cell lung cancer, melanoma, and ovarian cancer. Its ability to modulate the immune system and target tumor-associated macrophages makes it a potential candidate for combination therapies with immune checkpoint inhibitors or other immunotherapeutic agents. Research is ongoing to further evaluate its efficacy, safety, and potential as a novel cancer treatment.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :